H-FROGNCT07847710
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change.
- Minor Interventions modified
- Notable Start date pushed from Aug 1, 2026 to Sep 30, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Event-free survival (EFS)
Timeframe: From the start of treatment until the first EFS event, assessed up to 36 months.
Secondary (6)
Pathological complete response rate
Major pathological response rate
R0 resection rate
Disease-free survival
Overall survival
Show 1 moreShow less
Incidence and severity of adverse events
Arms and interventions
Combined treatment groupExperimental
Participants in this single arm will receive perioperative treatment with rilvegostomig alpha, famitinib malate, and HAIC-GEMOX before surgery, followed by postoperative adjuvant therapy with rilvegostomig alpha plus capecitabine or S-1 when applicable.
Drugs: Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin, Capecitabine, S-1
Procedures: hepatic arterial infusion chemotherapy (HAIC)
Sites
1 site in 1 country
- The First Affiliated Hospital with Nanjing Medical UniversityNanjing, Jiangsu, China